A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Depression impacts an estimated 18 million Americans each year, yet depression screening rarely occurs in the outpatient setting.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...

Depression is prevalent in children, requiring early diagnosis and treatment. Learn about child depression symptoms, causes ...

The umbrella term is called photobiomodulation therapy, which covers other colors, or wavelengths, that have health benefits.

Prompted by Blue Monday, the BBC's special correspondent reflects on his struggle to find balance and joy in life - and a ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...